the good news is - phase 3 clinical trials have been completed and the alternative analysis approach in view of the absence of control group placebo data. if the data is accepted by the regulatory bodies, it can then proceed to phase 4 - post marketing surveillance where the drug is marketed and available to the general public; larger sample size to study long term risks and benefits :)